Spike in Tobacco Usage, Smoking Behavior and Heritable Cancer Syndromes are Projected to Drive the Global Urological Cancer Market

Urological cancer is the growth of abnormal tissues in bladder, prostate, penile, testicular, and kidney. These abnormal tissues are referred to as tumor, which even spread in the surrounding tissues or muscles. As people get older, bladder cancer is more common in men than women. Signs and symptoms of a urological cancer depend on the type and stage of the cancer. In U.S., bladder cancer is the fourth most common cancer among men and the ninth most common among women.

According to UCSF Medical Center, more than 50,000 new cases of bladder cancer are diagnosed each year. Testicular cancer is the most common among men aged 15 to 44 years in the U.S. According to American Cancer Society, each year about 6,900 cases of testicular cancer are diagnosed and about 300 men die from it annually in the country. The diagnosis of urological cancers depends on the types of cancer and severity of the patient.

Obtain Report Details @ http://www.transparencymarketresearch.com/urological-cancer-market.html

Factors such as aging population, advanced health care services, rise in obesity incidence, increase in use of hormone therapies, and spike in tobacco usage, smoking behavior, and heritable cancer syndromes are projected to drive the global urological cancer market. Other factors such as new product innovation and research and development activities are likely to fuel the market. Increase in number of collaborations, partnerships, and mergers and acquisitions for the availability of urological cancer treatment drugs are some of the latest trends that have been observed in the market. However, asymptomatic nature of the disease and strict environmental regulations are expected to hinder the growth of the urological cancer market.

The urological cancer market has been segmented by cancer type, treatment type, end-user, and geography. In terms of cancer type, the market is classified into bladder cancer, prostate cancer, penile cancer, testicular cancer, and kidney cancer. In terms of treatment type, the market is classified into chemotherapy, hormonal therapy, and surgery & radiation therapy. In terms of end-user, the market is classified into hospitals, urological centers, oncology centers, and specialty clinics.

Geographically, the market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Geographically, North America dominates the urological cancer market due to growing number of geriatric population, availability of advanced health care solutions, new product innovation, developed health care infrastructure, and technological advancement, which in turn are likely to drive the market. Prostate cancer, for example, is the most common cancer among men in the U.S. One out of every 10 men is likely to develop the disease at some time in life — most often after age 50. Europe follows North America in the market share due to increase in research and development activities as well as rise in consumption of alcohol and smoking behavior.

For more information on this report, fill the form @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19601

According to NHS, prostate cancer is the most common cancer among men in the U.K., with over 40,000 new cases diagnosed every year. Asia Pacific is expected to grow at a higher rate owing to increase in population growth, rise in awareness among people, growth in health care expenditure, availability of treatment option, and research and development activities. Latin America and Middle East & Africa are further expected to create huge opportunities for the market due to high per capita expenditure, increase in private health insurance coverage, growth in awareness among people, and government initiatives.

Major players operating in this market include Pfizer Inc., Novartis International AG, Johnson & Johnson Private Limited, Astellas Pharma Inc., AstraZeneca Plc., GlaxoSmithKline plc, Sanofi S.A., Celgene Corporation, Eli Lilly and Company, Bristol-Myers Squibb Company, and F. Hoffmann-La Roche AG.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.